<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089203</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 32816, 826250</org_study_id>
    <nct_id>NCT03089203</nct_id>
  </id_info>
  <brief_title>CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer</brief_title>
  <official_title>PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm Phase I study to establish the safety and feasibility of&#xD;
      intravenously administered lentivirally transduced dual PSMA-specific/ TGFβ-resistant CAR&#xD;
      modified autologous T cells (CART-PSMA-TGFβRDN cells) in patients with metastatic castrate&#xD;
      resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I study evaluating the safety and feasibility of lentivirally transduced&#xD;
      PSMA-TGFβRDN autologous CAR T cells administered with and without cyclophosphamide in a 3+3&#xD;
      dose escalation design. Cohort 1 subjects (N=3 or 6) will receive a single dose of 1-3 x&#xD;
      107/m2 lentivirally transduced CART-PSMA-TGFβRDN cells on day 0 without any conditioning&#xD;
      chemotherapeutic regimen. If the number of manufactured CAR T cells does not meet the&#xD;
      pre-specified minimum infused dose of 1 x 107/m2 cells, then dose will not be administered,&#xD;
      and the subject will be replaced in the study. If 1 DLT/3 subjects occurs, the study will&#xD;
      enroll an additional 3 subjects at this dose level. If 0 DLT/3 subjects or 1 DLT/6 subjects&#xD;
      occurs, the study will advance to Cohort 2.&#xD;
&#xD;
      If 2 DLT/3 subjects occurs at dose of 1-3 x 107/m2 cells, then enrollment in this Cohort will&#xD;
      be stopped and the dose will be de-escalated by 10-fold to 1-3 x 106 cells/m2 (Cohort -1). In&#xD;
      this situation, up to 6 subjects will be enrolled in Cohort&#xD;
&#xD;
      -1. Cohort 2 subjects (N=3 or 6) will receive a single dose of 1-3 x 108/m2 lentivirally&#xD;
      transduced CART-PSMA-TGFβRDN cells on day 0 without any conditioning chemotherapeutic&#xD;
      regimen. If the number of manufactured CAR T cells does not meet the protocol-specified&#xD;
      minimum of 1 x 108/m2 cells, but does meet the minimum dose requirement of at least 1 x&#xD;
      107/m2 cells, then the subject may receive the dose and will not be included in the DLT&#xD;
      assessment for Cohort 2. This subject would be replaced for DLT assessment. If, however, the&#xD;
      number of manufactured CAR T cells does not meet the pre-specified minimum infused dose as&#xD;
      outlined for Cohort 1, then no dose will be administered, and the subject will be replaced in&#xD;
      the study. If 1 DLT/3 subjects occurs, the study will enroll an additional 3 subjects at this&#xD;
      dose level. If 0 DLT/3 subjects or 1 DLT/6 subjects occurs, the study will advance to Cohort&#xD;
      3. If 2 DLT/3 subjects occur, then the study will stop and declare maximum tolerated dose&#xD;
      (MTD). Cohorts 1 and 2 will serve to identify the MTD of CART-PSMA-TGFβRDN cells. The maximum&#xD;
      tolerated dose is defined as the highest dose at which 0/3 or 1/6 DLTs occur. Cohort 3&#xD;
      subjects (N=3 or 6) will receive a single infusion at the MTD of lentivirally transduced&#xD;
      CART-PSMA-TGFβRDN cells on day 0, following a single dose of 1.0 gram/m2 of cyclophosphamide&#xD;
      administered up to 4 days prior to the CAR T cells (day -3 ± 1 day). If 0 DLT /3 subjects&#xD;
      occur, the study will enroll an additional 3 patients to confirm tolerability. If 1 DLT/3&#xD;
      subjects occurs, the study will enroll an additional 3 subjects at this dose level. If two of&#xD;
      the initial three subjects experience a DLT, three additional patients will be accrued with a&#xD;
      dose reduction in the lymphodepleting chemotherapy to 500 mg/m2 administered up to 4 days&#xD;
      prior to the CAR T cells (day -3 ± 1 day). The DLT observation period will be 28 days. The&#xD;
      highest dose level where only 0/3 or 1/6 DLTs were observed in a given cohort will be defined&#xD;
      as the MTD. Adverse event reporting will begin on Day 0 (Cohorts 1 and 2) or Day -3 ±1 day&#xD;
      (Cohort 3) and continue through 2 years after the infusion or until subjects begin an&#xD;
      alternative cancer-related treatment, whichever comes first. While on study, subjects will be&#xD;
      continually reassessed for evidence of acute and cumulative toxicities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">September 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>I. Adverse Events experienced by subjects infused with CART-PSMA- TGFβRDN cells</measure>
    <time_frame>week -8 through end of study approximately 24 months after infusion</time_frame>
    <description>using CTCAE v 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>II. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells</measure>
    <time_frame>Week -2, day 28. month 3 and 6</time_frame>
    <description>using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>III. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells</measure>
    <time_frame>Week -2, day 28. month 3 and 6</time_frame>
    <description>PCWG2 criteria for bone disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IV. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells</measure>
    <time_frame>Week -2, day 28. month 2, 3 and 6</time_frame>
    <description>Serum PSA measurements</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CART T cells 1-3x10^7 Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cart T cells 1-3x10^8 Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort -3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day Day -3 CART T cells 1-3x10^7 Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART T cells</intervention_name>
    <description>1-3x10^7</description>
    <arm_group_label>Cohort -3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART T cells</intervention_name>
    <description>1-3 x 10^8</description>
    <arm_group_label>Cohort -3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 1g/m^2</intervention_name>
    <description>day -3 of cohort 3 subjects only</description>
    <arm_group_label>Cohort -3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART T cells</intervention_name>
    <description>MTD given in Cohort 3 only</description>
    <arm_group_label>Cohort -3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic castrate resistant prostate cancer&#xD;
&#xD;
             ≥10% tumor cells expressing PSMA as demonstrated by immunohistochemistry analysis on&#xD;
             fresh tissue.&#xD;
&#xD;
          -  Radiographic evidence of osseous metastatic disease and/or measurable, non-osseous&#xD;
             metastatic disease (nodal or visceral)&#xD;
&#xD;
          -  Patients &gt; or = 18 years of age&#xD;
&#xD;
          -  ECOG performance status of 0 - 1&#xD;
&#xD;
          -  Adequate organ function, as defined by:&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 cc/min&#xD;
&#xD;
          -  Serum total bilirubin &lt; 1.5x ULN&#xD;
&#xD;
          -  Serum ALT/AST &lt; 2x ULN&#xD;
&#xD;
          -  Adequate hematologic reserve within 4 weeks of study enrollment as defined by:&#xD;
&#xD;
          -  Hgb &gt; 10 g/dl&#xD;
&#xD;
          -  PLT &gt; 100 k/ul&#xD;
&#xD;
          -  ANC &gt; 1.5 k/ul&#xD;
&#xD;
          -  Note: Subjects must not be transfusion dependent&#xD;
&#xD;
          -  Evidence of progressive castrate resistant prostate adenocarcinoma, as defined by:&#xD;
&#xD;
          -  Castrate levels of testosterone (&lt; 50 ng/ml) with or without the use of androgen&#xD;
             deprivation therapy AND&#xD;
&#xD;
          -  Evidence of one of the following measures of progressive disease in the 12 weeks&#xD;
             preceding study enrollment: soft tissue progression by RECIST 1.1 criteria, osseous&#xD;
             disease progression with 2 or more new lesions on bone scan(as per PCWG2 criteria),&#xD;
             increase in serum PSA of at least 25% and an absolute increase of 2ng/ml or more from&#xD;
             nadir (as per PCWG2 criteria)&#xD;
&#xD;
          -  Prior therapy with at least one standard 17α lyase inhibitor or second-generation&#xD;
             anti-androgen therapy for the treatment of metastatic castrate resistant prostate&#xD;
             cancer&#xD;
&#xD;
          -  Provides written informed consent&#xD;
&#xD;
          -  Subjects of reproductive potential must agree to use acceptable birth control methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with an immune-based therapy for the treatment of prostate cancer,&#xD;
             including cancer vaccine therapies (such as SipuleucelT, PROSTVAC) are allowable.&#xD;
             Under protocol-specified conditions, immune checkpoint inhibitors,radium-223 and&#xD;
             immunoconjugate therapies are also allowable.&#xD;
&#xD;
          -  History of an active non-curative non-prostate primary malignancy within the prior 5&#xD;
             years&#xD;
&#xD;
          -  Subjects who require the chronic use of systemic corticosteroid therapy. Patients may&#xD;
             be on a low dose of steroids (≤10mg equivalent of prednisone).&#xD;
&#xD;
          -  Subjects with Class III/IV cardiovascular disability according to the New York Heart&#xD;
             Association Classification&#xD;
&#xD;
          -  Subjects with symptomatic vertebral metastases affecting spinal cord function (as&#xD;
             determined by clinical history, physical exam, or MRI imaging)&#xD;
&#xD;
          -  History of active or severe autoimmune disease requiring immunosuppressive therapy&#xD;
&#xD;
          -  Patients with ongoing or active infection.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study product excipients (human serum&#xD;
             albumin, DMSO,and Dextran 40)&#xD;
&#xD;
          -  Active hepatitis B, hepatitis C or HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtiy of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

